Kodiak Sciences Inc stocks have been trading up by 91.31 percent amid bullish sentiment on its latest ophthalmology pipeline progress
Click Here for a Millionaire's POV on Trading KOD
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- UBS reiterates a Buy on Kodiak Sciences, projecting upside to an $80 target versus a current share price near $31 and pointing to Phase III wet AMD trials for tarcocimab and KSI-501.
- Multiple near-term catalysts for KOD include September topline data, an AAO October presentation, and December data readouts, all tied to its retina pipeline.
- Goldman Sachs resumes coverage of Kodiak Sciences with a Neutral rating and a $36 price target, within a broadly constructive biotech backdrop.
- Pivotal Phase 3 DAYBREAK topline results for Zenkuda (tarcocimab tedromer) and KSI-501 in wet AMD are set for 2026/09/28, spotlighting Kodiak Sciences’ late-stage retina program.
Live Update At 09:17:15 EDT: On Monday, September 28, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 91.31%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Kodiak Sciences (KOD) is trading like a classic biotech catalyst setup. The multi-day chart shows KOD consolidating mostly in the low-to-mid $30s, with recent closes clustering between about $31 and $35. That tells traders the stock has already priced in some optimism, but not the kind of blow-off move you’d expect if everyone were all-in on a win.
Intraday, KOD has printed a violent premarket spike from the low $30s to above $60, with wide 5‑minute candles and big ranges. That kind of action screams “event-driven trading” and confirms that short-term players are crowding in ahead of the Phase 3 data. Volatility is the main product here.
On the fundamentals, Kodiak Sciences is still a development-stage biotech. The latest quarter shows a net loss of about $65.6M and operating cash outflow near $46.2M, with research expense above $56M. KOD carries about $125.9M in cash and cash equivalents and roughly $78.6M in working capital, giving it some runway but not endless time. Profitability ratios are sharply negative, as you’d expect for a company without approved products yet.
More Breaking News
- GENI Stock Pops As Genius Sports Launches Prediction.com
- EDBL Surges As Edible Garden Wins New Walmart Deal
- American Airlines Stock Grinds Higher As Growth Story Builds
- MHK Jumps As Mohawk Industries Plans Aggressive Buybacks
For traders, the message is simple: KOD is a story stock anchored almost entirely to its clinical and regulatory milestones.
Why Traders Are Watching Kodiak Sciences Now
Kodiak Sciences is front and center on many trading screens because the calendar is loaded and the Street is split on how far KOD can run. UBS is leaning hard into the bullish side, reiterating a Buy rating on KOD with an $80 price target versus a recent share price around $31. That is more than 2x upside if the thesis plays out. Their call hangs on Phase III wet age-related macular degeneration (AMD) trials for tarcocimab and KSI-501, where they expect non-inferiority to Eylea with the potential for extended dosing intervals.
For traders, that dosing angle matters. If Kodiak Sciences shows that Zenkuda (tarcocimab) and KSI-501 can match Eylea while letting patients come in less often, that is an easy story for the market to understand. It gives KOD a clear competitive hook and could justify the aggressive UBS target. Add in multiple near-term readouts — September topline data, an American Academy of Ophthalmology (AAO) presentation in October, and more data in December — and you have a textbook series of volatility catalysts.
At the same time, Goldman Sachs brings a more cautious lens, restarting coverage of Kodiak Sciences at Neutral with a $36 target. That’s only modestly above where KOD has been trading, even though Goldman highlights a friendlier biotech backdrop thanks to M&A, clinical wins, and a more supportive regulatory environment. The gap between the UBS $80 call and Goldman’s $36 target tells traders this is not a consensus layup. The pivotal DAYBREAK topline results on 2026/09/28 will likely decide which camp looks smarter.
Conclusion
KOD is the kind of setup active traders study for years: clear binary-style catalyst, big analyst disagreement, heavy premarket volatility, and a development-stage balance sheet that leaves little room for complacency. Kodiak Sciences has around $125.9M in cash, continues to burn tens of millions each quarter on R&D, and posts deeply negative returns on equity and assets. None of that scares seasoned biotech traders; it just underlines that the entire story rests on what the retina pipeline delivers.
The upcoming DAYBREAK Phase 3 topline readout for Zenkuda and KSI-501 in wet AMD on 2026/09/28 is the focal point. If Kodiak Sciences shows solid non-inferiority to Eylea and a credible pathway to longer dosing intervals, the market has a concrete reason to move KOD closer to the UBS vision. Weak or messy data, and the Goldman-style Neutral stance will look more realistic, with traders forced to reassess risk, possible dilution, and the longer-term cash runway.
For short-term players, the key is preparation — know the dates, map the levels, and plan risk before the news hits. As Tim Sykes likes to say, “The market rewards preparation, not prediction.” In the same spirit, as Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” KOD is handing traders a packed catalyst calendar; the edge comes from disciplined trading around those moves, not guessing the science.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.